Lexeo Therapeutics, Inc.
Biotechnology company · New York, United States · Nasdaq: LXEO
Lexeo Therapeutics, Inc. is a biotechnology company headquartered in New York, United States. Its shares trade on Nasdaq under the ticker LXEO. It has received 6 US government small-business research awards (SBIR/STTR) from health agencies, $2.9 million in total, most recently in 2020.
Lexeo Therapeutics at a glance
What does Lexeo Therapeutics do?
US government research funding
6 SBIR/STTR small-business research awards from US health agencies, $2.9 million in total (2018 to 2020). NIH funding came from the National Heart, Lung, and Blood Institute, National Institute on Alcohol Abuse and Alcoholism, National Institute of Neurological Disorders and Stroke.
Frequently asked questions about Lexeo Therapeutics
Where is Lexeo Therapeutics headquartered?
Lexeo Therapeutics, Inc. is headquartered in New York, United States.
What does Lexeo Therapeutics do?
Lexeo Therapeutics, Inc. is a biotechnology company. Its SEC industry classification is Biological Products, (No Diagnostic Substances).
Is Lexeo Therapeutics a public company?
Yes. Lexeo Therapeutics, Inc. trades on Nasdaq under the ticker LXEO.
Similar companies
- MiNK Therapeutics, Inc.New York City, New York, United States
- IN8BIO, Inc.New York City, New York, United States
- Anavex Life Sciences Corp.New York City, New York, United States
- Brainstorm Cell Therapeutics Inc.New York City, New York, United States
- Bioincept LLCNew York City, New York, United States
- Protara Therapeutics, Inc.New York City, New York, United States
- Ancilia Biosciences, Inc.New York City, New York, United States
- Microstructure Imaging, Inc.New York City, New York, United States
Need a CRO or CDMO for your next study?
Compare transparent quotes from research and manufacturing partners, then contract once. Free for buyers.
Compare quotesSources
Location data: GeoNames (geonames.org), CC BY 4.0.
Last updated 2026-09-23.